Downregulation of calcineurin activity in cervical carcinoma

Cancer Cell International

Volumn 5, Issue , 2005, Pages

  Padma, Samavedam ^a   Sowjanya, A Pavani ^a   Poli, Usha Rani ^b   Jain, Meenakshi ^c   Rao, Bachi N ^b   Ramakrishna, Gayatri ^a  

^a CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

^b MNJ Inst of Oncology/Reg Cancer   (India)

^c Mediciti Hospitals   (India)

Author keywords

Calcineurin (PP2B CaN); Calmodulin (CaM); Cervical neoplasia; Squamous cell carcinoma (SCC)

Indexed keywords

CALCINEURIN; CALMODULIN; TRANSCRIPTION FACTOR NFAT;

ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CANCER GRADING; CANCER SCREENING; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA BINDING; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GEL MOBILITY SHIFT ASSAY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INFECTION RISK; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; WART VIRUS;

EID: 18144372366     PISSN: 14752867     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2867-5-7     Document Type: Article

References (55)

1. Franco EL, Schlecht NF, Saslow D: The epidemiology of cervical cancer. Cancer J. 2003, 9:348-59.
2. Bosch FX, de Sanjose S: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr. 2003, 31:3-13.
3. Shanta V, Krishnamurthi S, Gajalakshmi CK, Swaminathan R, Ravichandran K: Epidemiology of cancer of the cervix: global and national perspective. J Indian Med Assoc. 2000, 98:49-52.
4. Pal SK, Mittal B: Improving cancer care in India: prospects and challenges. Asian Pac J Cancer Prev. 2004, 5:226-8.
5. Castellsague X, Bosch FX, Munoz N: Environmental co-factors in HPV carcinogenesis. Virus Res. 2002, 89:191-9.
6. Wang SS, Hildesheim A: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr. 2003, 31:35-40.
7. zur Hausen H: Papillomaviruses in human cancers. Proc Assoc Am Physicians. 1999, 111:581-7.
8. Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, Krishna S: Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J Virol. 2004, 78:5934-45.
9. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY: PIK3CA as an oncogene in cervical cancer. Oncogene. 2000, 19:2739-44.
10. Liu B, Fang M, Lu Y, Lu Y, Mills GB, Fan Z: Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br J Cancer. 2001, 85:303-11.
11. Cheung TH, Yu MM, Lo KW, Yim SF, Chung TK, Wong YF: Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. Cancer Lett. 2001, 166:199-206.
12. Skomedal H, Kristensen GB, Lie AK, Holm R: Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol. 1999, 73:223-8.
13. Hashiguchi Y, Tsuda H, Nishimura S, Inoue T, Kawamura N, Yamamoto K: Relationship between HPV typing and the status of G2 cell cycle regulators in cervical neoplasia. Oncol Rep. 2004: 12587-91.
14. Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, Vela-Chavez T, Candelaria M, Cetina L, Vidal S, Duenas-Gonzalez A: HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer. 2004, 4:59.
15. Shen MR, Chou CY, Hsu KF, Ellory JC: Osmotic shrinkage of human cervical cancer cells induces an extracellular Cl-dependent nonselective cation channel, which requires p38 MAPK. J Biol Chem. 2002, 277:45776-84.
16. Naeger LK, Goodwin EC, Hwang ES, DeFilippis RA, Zhang H, DiMaio D: Bovine papillomavirus E2 protein activates a complex growth-inhibitory program in p53-negative HT-3 cervical carcinoma cells that includes repression of cyclin A and cdc25A phosphatase genes and accumulation of hypophosphorylated retinoblastoma protein. Cell Growth Differ. 1999, 10:413-22.
17. Cheung TH, Lo KW, Yim SF, Chan LK, Heung MS, Chan CS, Cheung AY, Chung TK, Wong YF: Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol. 2004, 93:621-7.
18. Narayan G, Pulido HA, Koul S, Lu XY, Harris CP, Yeh YA, Vargas H, Posso H, Terry MB, Gissmann L, Schneider A, Mansukhani M, Rao PH, Murty VV: Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene. 2003, 22:3489-99.
19. Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev: 2000, 80:1483-521.
20. Im SH, Rao A: Activation and deactivation of gene expression by Ca2+/calcineurin-NFAT-mediated signaling. Mol Cells. 2004, 181-9.
21. Graef IA, Chen F, Chen L, Kuo A, Crabtree GR: Signals transduced by Ca[2+]/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell. 2001, 105:863-75.
22. Lambrechts D, Carmeliet P: Sculpting heart valves with NFATc and VEGF. Cell. 2004, 118:532-4.
23. Schulz RA, Yutzey KE: Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development. Dev Biol. 2004, 266:1-16.
24. Lee JI, Ahnn J: Calcineurin in animal behavior. Mol Cells 2004, 17:390-6.
25. Sugiura R, Sio SO, Shuntoh H, Kuno T: Molecular genetic analysis of the calcineurin signaling pathways. Cell Mol Life Sci. 2001, 58:278-88.
26. Mansuy IM: Calcineurin in memory and bidirectional plasticity. Biochem Biophys Res Commun. 2003, 311:1195-208.
27. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998, 93:215-28.
28. Ladner CJ, Czech J, Maurice J, Lorens SA, Lee JM: Reduction of calcineurin enzymatic activity in Alzheimer's disease: correlation with neuropathologic changes. J Neuropathol Exp Neurol. 1996: 55924-31.
29. Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD, Zeng H, Caron MG, Tonegawa S: Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A. 2003, 100:8987-92.
30. Gooch JL, Pergola PE, Guler RL, Abboud HE, Barnes JL: Differential expression of calcineurin A isoforms in the diabetic kidney. J Am Soc Nephrol. 2004, 15:1421-9.
31. Fuentes JJ, Genesca L, Kingsbury TJ, Cunningham KW, Perez-Riba M, Estivill X, de la Luna S: DCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum Mol Genet. 2000: 9:1681-90.
32. Lian Q, Ladner CJ, Magnuson D, Lee JM: Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex. Exp Neurol. 2001: 167:158-65.
33. Asai A, Qiu J, Narita Y, Chi S, Saito N, Shinoura N, Hamada H, Kuchino Y, Kirino T: High level calcineurin activity predisposes neuronal cells to apoptosis. J Biol Chem. 1999, 274:34450-8.
34. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, McKeon F, Bobo T, Franke TF, Reed JC: Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999, 284339-43.
35. Baksh S, DeCaprio JA, Burakoff SJ: Calcineurin regulation of the mammalian G0/G1 checkpoint element, cyclin dependent kinase 4. Oncogene. 2000: 19:2820-7.
36. Kahl CR, Means AR: Regulation of cell cycle progression by calcium/calmodulin dependent pathways. Endocr Rev. 2003, 24 719-36.
37. Andre N, Roquelaure B, Conrath J: Molecular effects of cyclosporine and oncogenesis: a new model. Med Hypotheses. 2004:63[4]:647-52.
38. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999, 397:530-4.
39. Padma S, Subramanyam C: Clinical significance of serum calcineurin in acute leukemia. Clin Chim Acta. 2002, 321 17-21.
40. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM: Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a singlehybridization, reverse line blot detection method. J Clin Microbiol. 1998, 36:3020-7.
41. Sanli UA, Uslu R, Karabulut B, Sezgin C, Selvi N, Aydin HH, Saydam G, Goker E, Omay SB: Alterations in the activity and expression of serine/threonine protein phosphatases during all trans retinoic acid-induced apoptosis in breast cancer cells. Oncol Rep. 2003, 10:2083-8.
42. 2+ center at the enzyme active site. J Biol Chem. 2002, 277:5962-9.
43. Ullrich V, Namgaladze D, Frein D: Superoxide as inhibitor of calcineurin and mediator of redox regulation. Toxicol Lett. 2003, 139:107-10.
44. Wang X, Culotta VC, Klee CB: Superoxide dismutase protects calcineurin from inactivation. Nature. 1996, 383:434-7.
45. Ahmed MI, Fayed ST, Hossein H, Tash FM: Lipid peroxidation and antioxidant status in human cervical carcinoma. Dis Markers. 1999, 15:283-91.
46. Manju V, Balasubramanian V, Nalini N: Oxidative stress and tumor markers in cervical cancer patients. J Biochem Mol Biol Biophys. 2002, 6:387-90.
47. Giuliano A: Cervical carcinogenesis: the role of co-factors and generation of reactive oxygen species. Salud Publica Mex. 2003, 45:S354-60.
48. Choi H, Park CS, Kim BG, Cho JW, Park JB, Bae YS, Bae DS: Creatine kinase B is a target molecule of reactive oxygen species in cervical cancer. Mol Cells. 2001, 12:412-7.
49. Shirane M, Nakayama KI: Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol. 2003, 5:28-37.
50. Lin HY, Michtalik HJ, Zhang S, Andersen TT, Van Riper DA, Davies KK, Ermak G, Petti LM, Nachod S, Narayan AV, Bhatt N, Crawford DR: Oxidative and calcium stress regulate DSCR1 (Adapt78/MCIP1) protein. Free Radic Biol Med. 2003, 35:528-39.
51. Stoler MH: The pathology of cervical neoplasia. In Rohan TE and Shah KV eds. Cervical Cancer: From etiology to prevention. Kluwer Academic Publishers. 2004 USA. 3-60.
52. Neal JW, Clipstone NA: A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. J Biol Chem. 2003, 278:17246-54.
53. Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A: The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol. 2002, 4:540-4.
54. 2+-dependent signal transduction pathways. J Immunol. 1995, 155:4685-91.
55. Nair A, Venkatraman M, Maliekal TT, Nair B, Karunagaran D: NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene. 2003, 22:50-8.